TrialCancer immunology, immunotherapy : CII2022

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.

Geoffroy Bilger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.